Table 1 H3K27me3 and EZH2 IHC expression in melanoma metastases prior to anti-PD-1 inhibition
H3K27me3+ | H3K27me3− | p value | EZH2+ | EZH2− | p value | ||
|---|---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | n (%) | |||
Number | 44 | 29 (65.9) | 15 (34.1) | 6 (13.6) | 38 (86.4) | ||
Gender | |||||||
Female | 15 (34.1) | 9 (60.0) | 6 (40.0) | p = .552 | 0 (0) | 15 (100) | p = .058 |
Male | 29 (65.9) | 20 (69.0) | 9 (31.0) | 6 (20.7) | 23 (79.3) | ||
Location of metastases | |||||||
Local tumor recurrence | 5 (11.4) | 4 (80.0) | 1 (20.0) | 0 (0) | 5 (100) | ||
Cutaneous metastases | 16 (36.4) | 11 (69.0) | 5 (31.0) | 2 (12.5) | 14 (87.5) | ||
Lymph node metastases | 13 (29.5) | 7 (53.8) | 6 (46.2) | p = .367 | 2 (15.4) | 11 (84.6) | p = .433 |
Lung metastases | 5 (11.4) | 2 (40.0) | 3 (60.0) | 0 (0) | 5 (100) | ||
Brain metastases | 3 (6.8) | 3 (100) | 0 (0) | 1 (33.3) | 2 (66.6) | ||
Abdominal metastases | 2 (4.5) | 2 (100) | 0 (0) | 1 (50.0) | 1 (50.0) | ||
Response to anti-PD-1 blockade | |||||||
Non-responder | 20 (45.5) | 13 (65.0) | 7 (35.0) | p = .930 | 2 (10.0) | 18 (90.0) | p = .685 |
Responder | 24 (54.5) | 16 (66.7) | 8 (33.3) | 4 (16.7) | 20 (83.3) | ||
Tumor-infiltrating lymphocytes | |||||||
Absent | 35 (79.5) | 25 (71.4) | 10 (28.6) | p = .141 | 5 (14.3) | 30 (85.7) | p > .999 |
Non-brisk | 7 (15.9) | 4 (57.1) | 3 (42.9) | 1 (14.3) | 6 (85.7) | ||
Brisk | 2 (4.5) | 0 (0) | 2 (100) | 0 (0) | 2 (100) | ||